TCRX — Tscan Therapeutics Share Price
Last trade - 00:00- $309.25m
- $176.71m
- $21.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.79 | ||
| Price to Tang. Book | 2.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 23.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.76% | ||
| Return on Equity | -96.32% | ||
| Operating Margin | -689.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.08 | 10.14 | 13.54 | 21.05 | 7.85 | 3.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Directors
- David Southwell CEO (60)
- Gavin MacBeath CSO
- Shane Maltbie VFN
- Ann Hargraves VPR
- Heather Savelle VPR
- Henry Rath OTH
- Zoran Zdraveski OTH (51)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 17th, 2018
- Public Since
- July 16th, 2021
- No. of Shareholders
- 70
- No. of Employees
- 161
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 52,862,805
- Address
- 880 Winter Street, WALTHAM, 02451
- Web
- https://www.tscan.com
- Phone
- +1 8573999500
- Auditors
- Deloitte & Touche LLP
Upcoming Events for TCRX
Similar to TCRX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
As of Today at 23:51 UTC, shares in Tscan Therapeutics are trading at $6.50. This share price information is delayed by 15 minutes.
Shares in Tscan Therapeutics last closed at $6.50 and the price had moved by +129.68% over the past 365 days. In terms of relative price strength the Tscan Therapeutics share price has outperformed the S&P500 Index by +82.76% over the past year.
The overall consensus recommendation for Tscan Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Tscan Therapeutics does not currently pay a dividend.
Tscan Therapeutics does not currently pay a dividend.
Tscan Therapeutics does not currently pay a dividend.
To buy shares in Tscan Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.50, shares in Tscan Therapeutics had a market capitalisation of $343.61m.
Here are the trading details for Tscan Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TCRX
Based on an overall assessment of its quality, value and momentum Tscan Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Tscan Therapeutics is $12.57. That is 93.38% above the last closing price of $6.50.
Analysts covering Tscan Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.21 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tscan Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -1.23%.
As of the last closing price of $6.50, shares in Tscan Therapeutics were trading +9.68% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Tscan Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Tscan Therapeutics' management team is headed by:
- David Southwell - CEO
- Gavin MacBeath - CSO
- Shane Maltbie - VFN
- Ann Hargraves - VPR
- Heather Savelle - VPR
- Henry Rath - OTH
- Zoran Zdraveski - OTH